Imperial College London

ProfessorEricAboagye

Faculty of MedicineDepartment of Surgery & Cancer

Professor
 
 
 
//

Contact

 

+44 (0)20 3313 3759eric.aboagye

 
 
//

Assistant

 

Mrs Maureen Francis +44 (0)20 7594 2793

 
//

Location

 

GN1Commonwealth BuildingHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Contractor:2011,
author = {Contractor, KB and Kenny, L and Stebbing, J and Rosso, L and Ahmad, R and Jacob, J and Challapalli, A and Turkheimer, F and Al-Nahhas, A and Sharma, R and Coombes, RC and Aboagye, EO},
title = {[18F]-3'deoxy-3'-Fluorothymidine Positron Emission Tomography and Breast Cancer Response to Docetaxel},
url = {http://www.ncbi.nlm.nih.gov/pubmed/22028493},
year = {2011}
}

RIS format (EndNote, RefMan)

TY  - JOUR
AB - PURPOSE: To establish biomarkers indicating clinical response to taxanes, we determined whether early changes in [18F]-3'deoxy-3'-fluorothymidine positron emission tomography (FLT-PET) can predict benefit from docetaxel therapy in breast cancer.EXPERIMENTAL DESIGN: This was a prospective unblinded study in 20 patients with AJCC stage II-IV breast cancer unresponsive to first-line chemotherapy or progressing on previous therapy. Individuals underwent a baseline dynamic FLT-PET scan followed by a scan two weeks after initiating the first or second cycle of docetaxel. PET variables were compared to anatomical response mid-therapy (after 3 cycles). RESULTS: Average and maximum tumor standardized uptake values at 60 min (SUV60,av and SUV60,max) normalized to body surface area ranged between 1.7 and 17.0, and 5.6 and 26.9 x 10-5 m2/mL, respectively. Docetaxel treatment resulted in a significant decrease in FLT uptake (p=0.0003 for SUV60,av and p=0.0002 for SUV60,max). Reduction in tumor SUV60,av was associated with target lesion size changes mid-therapy (Pearson R for SUV60,av=0.64; p=0.004) and predicted mid-therapy target lesion response (0.85 sensitivity and 0.80 specificity). Decreases in SUV60,av in responders were due at least in part, to reduced net intracellular trapping of FLT (rate constant Ki). Docetaxel significantly reduced Ki by 51.1% (+/-28.4%, p=0.0009).CONCLUSIONS: Changes in tumor proliferation assessed by FLT-PET early after initiating docetaxel chemotherapy can predict lesion response mid-therapy with good sensitivity warranting prospective trials to assess the ability to stop therapy in the event of non-FLT-PET response.
AU - Contractor,KB
AU - Kenny,L
AU - Stebbing,J
AU - Rosso,L
AU - Ahmad,R
AU - Jacob,J
AU - Challapalli,A
AU - Turkheimer,F
AU - Al-Nahhas,A
AU - Sharma,R
AU - Coombes,RC
AU - Aboagye,EO
PY - 2011///
SN - 1078-0432
TI - [18F]-3'deoxy-3'-Fluorothymidine Positron Emission Tomography and Breast Cancer Response to Docetaxel
UR - http://www.ncbi.nlm.nih.gov/pubmed/22028493
ER -